Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323310 | 1.00 | LMNA (0.40) | LMNAHDAC2HDAC3HDAC1HDAC8 | |
| SCHEMBL1323721 | 1.00 | LMNA (0.40) | LMNAHDAC2HDAC3HDAC1HDAC8 | |
| SCHEMBL1323314 | 1.00 | LMNA (0.40) | LMNAHDAC2HDAC3HDAC1HDAC8 | |
| SCHEMBL1324278 | 0.95 | HDAC1 (0.39) | LMNAHDAC2HDAC3HDAC1HDAC8 | |
| SCHEMBL1324281 | 0.95 | HDAC1 (0.39) | LMNAHDAC2HDAC3HDAC1HDAC8 | |
| SCHEMBL1324320 | 0.84 | HDAC2 (0.57) | LMNAHDAC2HDAC3HDAC1HDAC8 | |
| SCHEMBL1324806 | 0.84 | HDAC2 (0.57) | LMNAHDAC2HDAC3HDAC1HDAC8 | |
| SCHEMBL1323451 | 0.84 | CYP1A2 (0.49) | LMNAHDAC2HDAC3HDAC1HDAC8 | |
| SCHEMBL1324240 | 0.84 | HDAC2 (0.57) | LMNAHDAC2HDAC3HDAC1HDAC8 | |
| SCHEMBL1323452 | 0.84 | CYP1A2 (0.49) | LMNAHDAC2HDAC3HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773310-B9 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2012-04-25 | — | — | EP | claimed |
| EP-1773310-B1 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-10-19 | — | — | EP | claimed |
| US-20080070974-A1 | Alpha, Beta-Unsaturated Sulfones, Sulfoxides, Sulfonimides, Sulfinimides, Acylsulfonamides and Acylsulfinamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-20 | — | — | US | claimed |
| EP-1773310-B9 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8058313-B2 | 4-((1E)-2-(((E)-2-fluoro-4-cyanostyrylsulfonyl)methylsulfonyl)vinyl)-3-fluoro-benzonitrile; mitogen activated protein kinase inhibitor; cell growth factor receptor antagonist; angiogenesis inhibitor, antiproliferative and anticarcinogenic agent; neurodegenerative diseases | Temple University—Of the Commonwealth System of Higher Education (US) | 2011-11-15 | — | — | US | disclosed |
| EP-1773310-B1 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20080070974-A1 | Alpha, Beta-Unsaturated Sulfones, Sulfoxides, Sulfonimides, Sulfinimides, Acylsulfonamides and Acylsulfinamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1773310-A2 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006025924-A2 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070974-A1 | Alpha, Beta-Unsaturated Sulfones, Sulfoxides, Sulfonimides, Sulfinimides, Acylsulfonamides and Acylsulfinamides and Therapeutic Uses Thereof | DEGS1, SULT1E1, PTDSS1 | LMNA 1859/4885HDAC2 571/4885HDAC3 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.